Core A: PI: David L. Ayares, PhD Abstract: Precise genetic manipulation of the pig genome through a combination of somatic cell nuclear transfer and sophisticated gene modification tools offers the opportunity to provide an unlimited source of human-compatible donor organs, cells, and tissues for transplantation. As Core A, Revivicor will apply their advanced transgenic pig production platform to provide the GE source pig organs (kidney, heart, lung, and liver) necessary to meet the goals of the specific aims in Project 1 and Project 2. Elimination of immunogenic Gal?1,3Gal (Gal) sugars through inactivation of the ?1,3-galactosyl transferase gene (GTKO) was a critical first step, resulting in the elimination of hyperacute rejection (HAR), and prolonged survival of xenografts in non- human primate studies, compared to wild-type controls. To provide further protection protection from non-gal-mediated humoral rejection, next-generation GTKO pigs were produced with constitutive high-level expression of the complement regulatory genes, hCD46 and hCD55, individually and as triple transgenic pigs. In addition, for inhibition of coagulation and thrombosis, human anti-coagulant genes (EPCR, CD39, TFPI, and thrombomodulin), under endothelial cell-specific promoter systems, were added alone or in combination to produce donor pigs with up to six genetic modifications. The use of multi-cistronic ?2A? vectors has facilitated the production of these multi- transgenic pigs in which the added genes are not only co-expressed, but co-integrated in the genome, thus allowing propagation of new lines with reduced transgene segregation. Core A will utilize this multi-transgenic 2A pig platform to produce multiple combinations of six-gene (6GE) pigs that have already shown improved efficacy, and will further modify the source pig to inhibit T cell activation (expression of a dominant negative inhibitor of SLA class II (CIITA), and immunomodulation, through overexpression of the ?cloaking gene?, human CD47, to prevent activation of monocytes and other immune cells. In addition, towards prevention of spontaneous aggregation and sequestration of recipient platelets (and resulting thrombocytopenia in NHP), specific exons of porcine vWF will be replaced by their human equivalents using gene editing nuclease technologies. Core A will identify the optimal multi- gene mix, with an efficacious balance of gene expression levels, bioactivity, and synergistic effects, while maintaining a healthy herd, as needed to support the aims of Project 1 & 2.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI090959-09
Application #
9321872
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
9
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Surgery
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Cooper, David K C (2017) Early clinical xenotransplantation experiences-An interview with Thomas E. Starzl, MD, PhD. Xenotransplantation 24:
Samy, Kannan P; Butler, James R; Li, Ping et al. (2017) The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation. J Immunol Res 2017:8415205
Iwase, Hayato; Liu, Hong; Li, Tao et al. (2017) Therapeutic regulation of systemic inflammation in xenograft recipients. Xenotransplantation 24:
Laird, Christopher T; Burdorf, Lars; French, Beth M et al. (2017) Transgenic expression of human leukocyte antigen-E attenuates GalKO.hCD46 porcine lung xenograft injury. Xenotransplantation 24:
Bottino, Rita; Knoll, Michael F; Graeme-Wilson, Joshua et al. (2017) Safe use of anti-CD154 monoclonal antibody in pig islet xenotransplantation in monkeys. Xenotransplantation 24:
Iwase, Hayato; Hara, Hidetaka; Ezzelarab, Mohamed et al. (2017) Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts. Xenotransplantation 24:
Gao, Bingsi; Long, Cassandra; Lee, Whayoung et al. (2017) Anti-Neu5Gc and anti-non-Neu5Gc antibodies in healthy humans. PLoS One 12:e0180768
Iwase, Hayato; Liu, Hong; Schmelzer, Eva et al. (2017) Transplantation of hepatocytes from genetically engineered pigs into baboons. Xenotransplantation 24:
Zhang, Zhongqiang; Hara, Hidetaka; Long, Cassandra et al. (2017) IMMUNE RESPONSES OF HLA-HIGHLY-SENSITIZED AND NONSENSITIZED PATIENTS TO GENETICALLY-ENGINEERED PIG CELLS. Transplantation :
Lee, Whayoung; Mammen, Alex; Dhaliwal, Deepinder K et al. (2017) Development of retrocorneal membrane following pig-to-monkey penetrating keratoplasty. Xenotransplantation 24:

Showing the most recent 10 out of 90 publications